{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:11:28Z","timestamp":1758935488455},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.leukres.2008.10.024","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T15:41:25Z","timestamp":1228491685000},"page":"645-648","source":"Crossref","is-referenced-by-count":2,"title":["Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease"],"prefix":"10.1016","volume":"33","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Cannella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Stefanizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelina","family":"Santopietro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"De Cuia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Diverio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.10.024_bib1","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukaemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.024_bib2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five years follow-up of patients receiving imatinib for chronic myeloid leukaemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.10.024_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2007.13.2373","article-title":"Long-term outcome of complete cytogenetic responders after imatinib 400mg in late chronic phase, Philadelphia positive chronic myeloid leukaemia: the GIMEMA Working Party on CML","volume":"26","author":"Palandri","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.10.024_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation n patients with chronic myelogenous leukaemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.024_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1620\/tjem.210.355","article-title":"Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukaemia","volume":"210","author":"Ishikawa","year":"2006","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.leukres.2008.10.024_bib6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukaemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.10.024_bib7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","author":"The Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.10.024_bib8","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.10.024_bib9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukaemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.10.024_bib10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1080\/10428190600565057","article-title":"Intermitent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing","volume":"47","author":"Faber","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2008.10.024_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","article-title":"Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia","volume":"101","author":"Burchert","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.024_bib12","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukaemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T22:51:26Z","timestamp":1545605486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608004815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0145212608004815"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.10.024","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}